Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PPP1R13L (ImmuneEditome ID:10848)

1. Gene summary of enriched editing regions for PPP1R13L

Gene summary

Gene information	Gene symbol	PPP1R13L
	Gene ID	10848
	GeneSynonyms	IASPP\|NKIP1\|RAI\|RAI4
	GeneCytomap	19q13.32
	GeneType	protein-coding
	GeneDescription	relA-associated inhibitor\|NFkB interacting protein 1\|PPP1R13B-like protein\|inhibitor of ASPP protein\|inhibitor of apoptosis stimulating protein of p53\|protein iASPP\|protein phosphatase 1, regulatory (inhibitor) subunit 13 like\|retinoic acid induced 4
	GeneModificationdate	20230517
	UniprotID	Q8WUF5;A0A024R0Q5;K7EPP1;K7EN03;K7EML6
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr19:45380552-45381343:-	ENST00000587270.4	ENSG00000104881.13	PPP1R13L	ncRNA_intronic	AluSx,(TA)n,(CA)n,(A)n,AluSx1	chr19:45380552-45381343:-.alignment
chr19:45383286-45383455:-	ENST00000587270.4	ENSG00000104881.13	PPP1R13L	ncRNA_intronic	AluSq2,AluY	chr19:45383286-45383455:-.alignment
chr19:45383286-45383455:-	ENST00000589858.1	ENSG00000104881.13	PPP1R13L	ncRNA_intronic	AluSq2,AluY	chr19:45383286-45383455:-.alignment
chr19:45384012-45384820:-	ENST00000587270.4	ENSG00000104881.13	PPP1R13L	ncRNA_intronic	AluSx3,AluSz6,AluSx,AluJo	chr19:45384012-45384820:-.alignment
chr19:45384012-45384820:-	ENST00000589858.1	ENSG00000104881.13	PPP1R13L	ncRNA_intronic	AluSx3,AluSz6,AluSx,AluJo	chr19:45384012-45384820:-.alignment
chr19:45386715-45391164:-	ENST00000587270.4	ENSG00000104881.13	PPP1R13L	ncRNA_intronic	AluJo,GA-rich,AluSx,AluJb,LTR2C,AluSg,AluSz,AluY,L1ME4a,MIR	chr19:45386715-45391164:-.alignment
chr19:45392873-45395166:-	ENST00000585905.1	ENSG00000104881.13	PPP1R13L	ncRNA_exonic	AluJb,AluSx4,(TA)n,AluSz,AluY,AluSq,MIR,MIRb	chr19:45392873-45395166:-.alignment
chr19:45392873-45395166:-	ENST00000587270.4	ENSG00000104881.13	PPP1R13L	ncRNA_exonic	AluJb,AluSx4,(TA)n,AluSz,AluY,AluSq,MIR,MIRb	chr19:45392873-45395166:-.alignment
chr19:45399843-45400734:-	ENST00000585905.1	ENSG00000104881.13	PPP1R13L	ncRNA_intronic	AluSz6,AluJb,MIR3	chr19:45399843-45400734:-.alignment

Top

2. Tumor-specific enriched editing regions for PPP1R13L

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr19:45392873-45395166:-	BRCA	EER	3.7939e-02
ENSG00000104881.13,PPP1R13L	BRCA	EAG	4.6652e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr19:45380552-45381343:-	HNSC	Path	EER	3.1602e-04	4.8121e-04	-0.5897

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr19:45392873-45395166:-	KIRC	EER	4.3151e-03	3.4211e-02	3.7225e-02
chr19:45386715-45391164:-	LUSC	EER	1.1936e-02	4.4488e-02	1.5992e+01

Top

3. Enriched editing regions and immune related genes for PPP1R13L

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr19:45392873-45395166:-

ESCA

EER

ENSG00000182700,IGIP

0.3262

1.0903e-02

1.1155e-08

0.4524

ALYREF;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FAM120A;FMR1;FXR2;GTF2F1;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LIN28;LIN28B;NOP58;PTBP1;RNF219;SND1;SRSF1;TAF15;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;ZNF184;SRSF3

Dendritic_cells_activated

GSVA_HALLMARK_MYC_TARGETS_V1

chr19:45392873-45395166:-

ESCA

EER

ENSG00000137033,IL33

0.2882

2.2809e-02

1.3001e-08

0.4505

ELAVL1;FBL;PTBP1;TAF15;UPF1;YTHDC1;ADAR

IL33

Macrophages_M0

GSVA_HALLMARK_KRAS_SIGNALING_UP

chr19:45392873-45395166:-

ESCA

EER

ENSG00000169744,LDB2

0.2903

2.5776e-02

7.8159e-10

0.4827

CNBP;CSTF2T;DGCR8;EIF4A3;ELAVL1;EWSR1;FBL;HNRNPM;IGF2BP1;IGF2BP2;NOP56;NOP58;PTBP1;SRSF10;TAF15;TROVE2;UPF1;ADAR;SRSF3

Mast_cells_resting

GSVA_HALLMARK_KRAS_SIGNALING_UP

chr19:45392873-45395166:-

ESCA

EER

ENSG00000185129,PURA

0.2804

4.0304e-02

9.6151e-08

0.4254

AUH;BCCIP;BUD13;CAPRIN1;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FXR1;FXR2;GTF2F1;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;MSI2;NOP56;NOP58;NUMA1;PRPF8;PTBP1;RANGAP1;RBM10;RBM27;RNF219;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184;SRSF3

PURA

Mast_cells_activated

GSVA_HALLMARK_MYC_TARGETS_V2

chr19:45392873-45395166:-

ESCA

EER

ENSG00000182700,IGIP

0.3262

1.0903e-02

1.1155e-08

0.4524

ALYREF;CNBP;CSTF2T;DICER1;EIF4A3;ELAVL1;FAM120A;FMR1;FXR2;GTF2F1;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LIN28;LIN28B;NOP58;PTBP1;RNF219;SND1;SRSF1;TAF15;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;ZNF184;SRSF3

Dendritic_cells_activated

GSVA_HALLMARK_MYC_TARGETS_V1

chr19:45392873-45395166:-

ESCA

EER

ENSG00000137033,IL33

0.2882

2.2809e-02

1.3001e-08

0.4505

ELAVL1;FBL;PTBP1;TAF15;UPF1;YTHDC1;ADAR

IL33

Macrophages_M0

GSVA_HALLMARK_KRAS_SIGNALING_UP

chr19:45392873-45395166:-

ESCA

EER

ENSG00000169744,LDB2

0.2903

2.5776e-02

7.8159e-10

0.4827

CNBP;CSTF2T;DGCR8;EIF4A3;ELAVL1;EWSR1;FBL;HNRNPM;IGF2BP1;IGF2BP2;NOP56;NOP58;PTBP1;SRSF10;TAF15;TROVE2;UPF1;ADAR;SRSF3

Mast_cells_resting

GSVA_HALLMARK_KRAS_SIGNALING_UP

chr19:45392873-45395166:-

ESCA

EER

ENSG00000185129,PURA

0.2804

4.0304e-02

9.6151e-08

0.4254

PURA

Mast_cells_activated

GSVA_HALLMARK_MYC_TARGETS_V2

More results

Top

4. Enriched editing regions and immune related splicing for PPP1R13L

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000104881.13,PPP1R13L

ESCA

EAG

ENSG00000189171.9

chr1

153626319:153626533:153627138:153627221

0.4056

1.9072e-03

3.1176e-07

0.4070

ACIN1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184

S100A13

T_cells_CD4_memory_resting

GSVA_HALLMARK_P53_PATHWAY

More results

Top

5. Enriched editing regions and immune infiltration for PPP1R13L

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr19:45392873-45395166:-	BLCA	EER	T_cells_CD4_memory_resting	1.8006e-02	0.1492
ENSG00000104881.13,PPP1R13L	BLCA	EAG	T_cells_CD4_memory_resting	3.4166e-02	0.1287
chr19:45392873-45395166:-	BRCA	EER	T_cells_gamma_delta	9.7821e-04	0.1783
ENSG00000104881.13,PPP1R13L	BRCA	EAG	Dendritic_cells_resting	2.7921e-02	-0.1109
chr19:45386715-45391164:-	CESC	EER	T_cells_regulatory_(Tregs)	5.2839e-04	-0.4010
chr19:45392873-45395166:-	CESC	EER	T_cells_CD4_memory_resting	2.6915e-02	0.1492
ENSG00000104881.13,PPP1R13L	CESC	EAG	T_cells_CD4_memory_resting	2.6502e-02	0.1457
chr19:45392873-45395166:-	CHOL	EER	Plasma_cells	3.8394e-03	0.6159
ENSG00000104881.13,PPP1R13L	CHOL	EAG	Plasma_cells	1.1695e-04	0.7173
ENSG00000104881.13,PPP1R13L	COAD	EAG	Dendritic_cells_activated	2.0846e-02	0.3598
chr19:45380552-45381343:-	ESCA	EER	T_cells_regulatory_(Tregs)	6.6824e-03	0.3944
chr19:45392873-45395166:-	ESCA	EER	Plasma_cells	3.5935e-02	0.1744
chr19:45399843-45400734:-	ESCA	EER	Macrophages_M0	1.2454e-02	-0.5233
ENSG00000104881.13,PPP1R13L	ESCA	EAG	B_cells_naive	3.4993e-02	0.1723
chr19:45386715-45391164:-	HNSC	EER	Macrophages_M1	5.2564e-04	0.5236
chr19:45392873-45395166:-	HNSC	EER	T_cells_follicular_helper	3.3507e-02	0.1403
ENSG00000104881.13,PPP1R13L	HNSC	EAG	T_cells_follicular_helper	4.7355e-02	0.1276
chr19:45380552-45381343:-	KIRC	EER	T_cells_regulatory_(Tregs)	4.8710e-02	-0.3759
chr19:45392873-45395166:-	KIRP	EER	T_cells_CD4_memory_activated	2.2274e-06	0.5638
ENSG00000104881.13,PPP1R13L	KIRP	EAG	T_cells_CD4_memory_activated	1.6107e-08	0.6173
ENSG00000104881.13,PPP1R13L	LIHC	EAG	Dendritic_cells_activated	9.6771e-05	0.6263
chr19:45386715-45391164:-	LUAD	EER	Macrophages_M0	5.3252e-03	0.4740
chr19:45392873-45395166:-	LUAD	EER	Mast_cells_activated	1.9808e-04	0.2512
ENSG00000104881.13,PPP1R13L	LUAD	EAG	Mast_cells_activated	2.3612e-03	0.2017
chr19:45380552-45381343:-	LUSC	EER	T_cells_CD4_memory_resting	2.1963e-02	0.3707
chr19:45386715-45391164:-	LUSC	EER	NK_cells_resting	2.9210e-02	-0.2034
chr19:45392873-45395166:-	LUSC	EER	Macrophages_M0	3.0006e-02	-0.1295
chr19:45392873-45395166:-	OV	EER	B_cells_memory	3.6626e-03	0.2077
ENSG00000104881.13,PPP1R13L	OV	EAG	B_cells_memory	4.3716e-03	0.2002
chr19:45380552-45381343:-	PAAD	EER	Plasma_cells	9.5476e-03	-0.5396
chr19:45392873-45395166:-	STAD	EER	T_cells_CD4_memory_activated	2.6253e-02	0.1580
ENSG00000104881.13,PPP1R13L	STAD	EAG	T_cells_CD4_memory_activated	9.3706e-03	0.1789
chr19:45392873-45395166:-	THCA	EER	Mast_cells_resting	1.3757e-02	0.1881
ENSG00000104881.13,PPP1R13L	THCA	EAG	Mast_cells_resting	9.6864e-03	0.1940
chr19:45392873-45395166:-	THYM	EER	Monocytes	1.1371e-02	0.5407
ENSG00000104881.13,PPP1R13L	THYM	EAG	Monocytes	2.0663e-02	0.5011
chr19:45392873-45395166:-	UCEC	EER	Macrophages_M1	4.2244e-02	0.2914
ENSG00000104881.13,PPP1R13L	UCEC	EAG	T_cells_regulatory_(Tregs)	9.0498e-03	0.3520

Top

6. Enriched editing regions and immune gene sets for PPP1R13L

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000104881.13,PPP1R13L	BLCA	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.6073e-02	0.1461
chr19:45380552-45381343:-	BLCA	GSVA_HALLMARK_APICAL_SURFACE	EER	1.2579e-02	0.2439
chr19:45392873-45395166:-	BLCA	GSVA_HALLMARK_UV_RESPONSE_DN	EER	2.0761e-02	0.1459
chr19:45392873-45395166:-	BRCA	GSVA_HALLMARK_HEME_METABOLISM	EER	2.3530e-05	0.2275
ENSG00000104881.13,PPP1R13L	BRCA	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.7177e-02	0.1202
chr19:45386715-45391164:-	BRCA	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	6.4043e-03	0.3633
chr19:45380552-45381343:-	CESC	GSVA_HALLMARK_COMPLEMENT	EER	2.3723e-02	0.2206
chr19:45392873-45395166:-	CESC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	1.2447e-02	0.1682
ENSG00000104881.13,PPP1R13L	CESC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	5.2922e-03	0.1825
chr19:45386715-45391164:-	CESC	GSVA_HALLMARK_NOTCH_SIGNALING	EER	1.1376e-02	0.2988
chr19:45392873-45395166:-	CHOL	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	4.4270e-03	0.6083
ENSG00000104881.13,PPP1R13L	CHOL	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	4.6965e-02	0.4183
chr19:45399843-45400734:-	ESCA	GSVA_HALLMARK_APICAL_SURFACE	EER	4.9096e-02	0.4242
ENSG00000104881.13,PPP1R13L	ESCA	GSVA_HALLMARK_P53_PATHWAY	EAG	8.1297e-03	-0.2154
chr19:45380552-45381343:-	ESCA	GSVA_HALLMARK_P53_PATHWAY	EER	6.8558e-03	-0.3933
chr19:45392873-45395166:-	ESCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.8688e-02	-0.1951
chr19:45380552-45381343:-	HNSC	GSVA_HALLMARK_ADIPOGENESIS	EER	4.8269e-02	-0.3464
ENSG00000104881.13,PPP1R13L	HNSC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	4.9479e-03	-0.1801
chr19:45386715-45391164:-	HNSC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	3.1723e-03	0.4551
chr19:45380552-45381343:-	KIRC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.6124e-03	0.5681
chr19:45392873-45395166:-	KIRP	GSVA_HALLMARK_P53_PATHWAY	EER	4.1415e-02	-0.2620
ENSG00000104881.13,PPP1R13L	KIRP	GSVA_HALLMARK_P53_PATHWAY	EAG	4.8941e-02	-0.2380
ENSG00000104881.13,PPP1R13L	LIHC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	6.5817e-03	0.4636
chr19:45386715-45391164:-	LUAD	GSVA_HALLMARK_P53_PATHWAY	EER	4.5600e-03	0.4814
ENSG00000104881.13,PPP1R13L	LUAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	4.5416e-02	0.1335
chr19:45392873-45395166:-	LUAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	4.5467e-02	0.1366
chr19:45380552-45381343:-	LUSC	GSVA_HALLMARK_NOTCH_SIGNALING	EER	1.4526e-02	0.3935
chr19:45392873-45395166:-	LUSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.4392e-02	0.1459
ENSG00000104881.13,PPP1R13L	LUSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.3795e-02	0.1437
chr19:45392873-45395166:-	OV	GSVA_HALLMARK_APICAL_SURFACE	EER	6.1880e-05	-0.2835
ENSG00000104881.13,PPP1R13L	OV	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	2.1431e-04	-0.2582
chr19:45380552-45381343:-	PAAD	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.3383e-03	0.6400
ENSG00000104881.13,PPP1R13L	PAAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	2.3090e-02	0.2330
chr19:45392873-45395166:-	PAAD	GSVA_HALLMARK_UV_RESPONSE_DN	EER	2.9271e-02	0.2274
ENSG00000104881.13,PPP1R13L	SARC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	3.2186e-02	-0.3482
chr19:45392873-45395166:-	SARC	GSVA_HALLMARK_HEME_METABOLISM	EER	2.7685e-02	-0.3722
chr19:45386715-45391164:-	STAD	GSVA_HALLMARK_IL2_STAT5_SIGNALING	EER	3.4751e-03	0.3033
chr19:45392873-45395166:-	STAD	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	7.2959e-04	0.2381
ENSG00000104881.13,PPP1R13L	STAD	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	6.4153e-04	0.2337
chr19:45392873-45395166:-	THCA	GSVA_HALLMARK_ADIPOGENESIS	EER	6.5101e-04	0.2582
ENSG00000104881.13,PPP1R13L	THCA	GSVA_HALLMARK_ADIPOGENESIS	EAG	2.4818e-03	0.2261
ENSG00000104881.13,PPP1R13L	THYM	GSVA_HALLMARK_PEROXISOME	EAG	3.9341e-03	0.6013
chr19:45392873-45395166:-	THYM	GSVA_HALLMARK_PEROXISOME	EER	1.8555e-03	0.6381
chr19:45392873-45395166:-	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	9.2924e-03	0.3680

Top

7. Enriched editing regions and drugs for PPP1R13L

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000104881.13,PPP1R13L	BLCA	DMOG	EAG	3.6817e-02	-0.1269
chr19:45380552-45381343:-	BLCA	Metformin	EER	5.6690e-03	-0.2695
chr19:45386715-45391164:-	BLCA	Erlotinib	EER	1.2356e-02	-0.2481
chr19:45380552-45381343:-	BRCA	Erlotinib	EER	2.6593e-02	-0.2912
chr19:45392873-45395166:-	BRCA	AZD6482	EER	6.3214e-03	-0.1485
ENSG00000104881.13,PPP1R13L	BRCA	DMOG	EAG	2.1783e-02	-0.1158
chr19:45386715-45391164:-	BRCA	Embelin	EER	2.0595e-02	0.3115
chr19:45380552-45381343:-	CESC	ATRA	EER	6.4563e-03	-0.2642
chr19:45392873-45395166:-	CESC	Docetaxel	EER	1.2979e-03	0.2155
ENSG00000104881.13,PPP1R13L	CESC	Docetaxel	EAG	8.8709e-04	0.2168
chr19:45386715-45391164:-	CESC	Metformin	EER	1.4518e-03	0.3709
chr19:45392873-45395166:-	CHOL	JNK.Inhibitor.VIII	EER	5.0002e-03	0.6018
ENSG00000104881.13,PPP1R13L	CHOL	AZD7762	EAG	3.1688e-03	-0.5880
chr19:45392873-45395166:-	ESCA	Epothilone.B	EER	1.6398e-04	0.3080
chr19:45399843-45400734:-	ESCA	JNK.Inhibitor.VIII	EER	1.2788e-02	0.5216
ENSG00000104881.13,PPP1R13L	ESCA	Cisplatin	EAG	3.4132e-04	0.2886
chr19:45380552-45381343:-	ESCA	FTI.277	EER	7.0404e-04	0.4815
chr19:45392873-45395166:-	HNSC	FH535	EER	1.1328e-02	0.1667
chr19:45380552-45381343:-	HNSC	MG.132	EER	1.3198e-02	0.4270
chr19:45386715-45391164:-	HNSC	CEP.701	EER	2.2067e-02	-0.3657
ENSG00000104881.13,PPP1R13L	HNSC	EHT.1864	EAG	7.8970e-03	-0.1704
ENSG00000104881.13,PPP1R13L	KIRC	DMOG	EAG	1.8403e-04	0.2426
chr19:45380552-45381343:-	KIRC	IPA.3	EER	7.6035e-03	-0.4936
chr19:45392873-45395166:-	KIRC	AZD.2281	EER	9.5660e-03	-0.1702
chr19:45392873-45395166:-	KIRP	BIRB.0796	EER	1.1223e-02	-0.3226
ENSG00000104881.13,PPP1R13L	KIRP	BIRB.0796	EAG	1.2335e-02	-0.2998
ENSG00000104881.13,PPP1R13L	LIHC	BMS.754807	EAG	3.9012e-05	-0.6688
chr19:45386715-45391164:-	LUAD	FTI.277	EER	3.4718e-02	-0.3687
chr19:45392873-45395166:-	LUAD	Bosutinib	EER	4.5215e-03	0.1929
ENSG00000104881.13,PPP1R13L	LUAD	Bosutinib	EAG	9.7329e-03	0.1720
chr19:45392873-45395166:-	LUSC	AUY922	EER	3.0034e-02	0.1295
chr19:45386715-45391164:-	LUSC	Bryostatin.1	EER	3.1350e-02	0.2009
ENSG00000104881.13,PPP1R13L	LUSC	Bryostatin.1	EAG	2.3439e-02	0.1324
chr19:45380552-45381343:-	LUSC	AKT.inhibitor.VIII	EER	1.3646e-02	-0.3968
ENSG00000104881.13,PPP1R13L	OV	Imatinib	EAG	2.7100e-04	0.2542
chr19:45386715-45391164:-	OV	EHT.1864	EER	1.7976e-02	-0.2973
chr19:45392873-45395166:-	OV	Imatinib	EER	1.2305e-04	0.2722
chr19:45380552-45381343:-	PAAD	CI.1040	EER	4.2856e-03	0.5844
chr19:45392873-45395166:-	PAAD	BX.795	EER	3.7518e-03	-0.2993
ENSG00000104881.13,PPP1R13L	PAAD	BIBW2992	EAG	1.1585e-02	0.2580
ENSG00000104881.13,PPP1R13L	PRAD	BAY.61.3606	EAG	2.5772e-02	-0.2854
chr19:45392873-45395166:-	PRAD	BIBW2992	EER	8.0707e-03	0.3537
ENSG00000104881.13,PPP1R13L	SARC	AZ628	EAG	3.5380e-02	0.3424
chr19:45392873-45395166:-	SARC	KU.55933	EER	2.6704e-02	0.3744
chr19:45386715-45391164:-	STAD	AZD7762	EER	2.4979e-02	-0.2350
chr19:45392873-45395166:-	STAD	Erlotinib	EER	3.4419e-03	0.2075
ENSG00000104881.13,PPP1R13L	STAD	FTI.277	EAG	2.0699e-02	0.1596
chr19:45392873-45395166:-	THCA	LFM.A13	EER	1.1492e-02	0.1929
ENSG00000104881.13,PPP1R13L	THCA	AG.014699	EAG	2.1534e-02	0.1727
ENSG00000104881.13,PPP1R13L	THYM	CCT018159	EAG	6.6520e-03	0.5728
chr19:45392873-45395166:-	THYM	CCT018159	EER	4.6490e-03	0.5925
ENSG00000104881.13,PPP1R13L	UCEC	AZD6244	EAG	6.5608e-03	-0.3689
chr19:45392873-45395166:-	UCEC	Lenalidomide	EER	2.2854e-03	-0.4258

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType